MIFEPRISTONE AND MISOPROSTOL
Information current as at: 1 June 2026
PBAC meeting date: July 2026
Submission Details
- Brand name:
-
- MS-2 Step®
- Form and strength:
-
- Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms
- Submission sponsor:
- MS HEALTH PTY LTD
- Condition/indication:
(therapeutic use) -
- Termination of an intra-uterine pregnancy
- Listing requested:
- To request a change to the existing listing of mifepristone and misoprostol for the termination of an intra-uterine pregnancy, such that the condition must be an intra-uterine pregnancy of up to 70 days of gestation (compared to 63 days of gestation with the existing listing).
- Funding program:
- PBS General Schedule
- Request authority level:
- Authority Required (STREAMLINED)
- PBAC Submission type:
- Change to existing listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - July 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 25/03/2026 and close 20/05/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
1235
Page last updated
31 May 2026
v.9.19